David Klonoff, MD
Volunteer Clinical Professor
Medicine
School of Medicine

415-353-2350

David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center (Sutter Health) in San Mateo, California and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award.

Show full bio (610 words) Hide full bio

He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. He received the IEEE Standards Association Conformity Assessment Award in 2022. He was named by Avant-garde Health to their 2025 All-Stars list of the top 1% of US endocrinology researchers. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. He is the Founding Editor-in-Chief of Journal of Diabetes Science and Technology (the world's first purely electronic diabetes journal) and he also founded Diabetes Technology & Therapeutics. He has authored over 400 publications in PubMed journals including four of the first ten articles on diabetes device cybersecurity. His h-index is 71 and i10-index is 245. Dr. Klonoff has been a PI on over 130 clinical trials of diabetes drugs and devices. He was the lead investigator for the first multicenter RCT of an outpatient artificial pancreas product and chair of the SAB for the first FDA-cleared insulin patch pump. Dr. Klonoff coined the term “diabetes technology” and founded the Diabetes Technology Meeting, which is co-presented by Diabetes Technology Society and the American Diabetes Association. He is senior editor of the world’s first three books about diabetes digital health. He published the first article showing in COVID-19, correction of hyperglycemia of diabetes increases recovery. Dr. Klonoff has chaired or served on 67 grant review panels: NIH, CDC, NASA, NSF, US Army, NOAA, ADA, JDRF plus agencies in 12 foreign countries. He is Chair of the Scientific Advisory Board of the TexasA&M/UCLA/FIU/Rice PATHS-UP Engineering Research Center. Dr. Klonoff is the Medical Director of the Diabetes Research Hub repository for diabetes research data. He is co-chair of iCoDE and iCOde2, the first standards for automatic uploading of CGM data and insulin dosing data from wireless devices into the electronic health record. Dr. Klonoff created the Glycemia Risk Index to describe the quality of glycemia of continuous glucose monitor tracings and the DTS Error Grid /Trend Matrix to define the clinical accuracy of continuous glucose monitors and blood glucose monitors. He chaired the first and second CLSI POCT05 Performance Metrics for Continuous Interstitial Glucose Monitoring Panel, and the Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline Panel. Dr. Klonoff is a graduate of UC Berkeley, where he was elected to Phi Beta Kappa in his junior year, and UCSF Medical School, where he was elected to Alpha Omega Alpha in his junior year. His postgraduate training included two years at UCLA Hospital and three years at UCSF Hospitals. He chaired the SC award-winning IEEE 2621 Standards for Wireless Diabetes Device Security Assurance Committee and he chaired DTSec and DTMoSt, the world’s 1st and 2nd consensus medical device cybersecurity standards. For this work Dr. Klonoff was featured in an article in Wired Magazine.

PRESENT ACADEMIC AND PROFESSIONAL POSITION 2006-Present Editor-in-Chief, Journal of Diabetes Science and Technology 2000-Present Medical Director, Dorothy L. and James E. Frank Diabetes Research Institute, Mills-Peninsula Medical Center (Sutter Health), San Mateo, California 1995-Present Clinical Professor, Department of Medicine, U.C. San Francisco EDUCATION 1972-1976 University of California at San Francisco: M.D. 1968-1972 University of California at Berkeley: B.S. in Genetics (with Highest Honors)

Awards

Show all (11) Hide

  • Research All-Star (Top 1% of US Endocrinology Researchers), Avant-garde Health, 2025
  • Conformity Assessment Award, Institute of Electrical and Electronics Engineering (IEEE) Standards Association, 2022
  • Outstanding Physician-Clinician in Diabetes Award, American Diabetes Association, 2019
  • Visiting Professor, Tokyo University of Agriculture and Technology, Graduate School of Engineering, 2016
  • FRCP (Edin), Fellow of Royal College of Physicians of Edinburgh, 2014
  • Fellow AIMBE, American Institute of Medical and Biological Engineering, 2013
  • Gold Medal Oration Award, Madras (India) Diabetes Research Foundation, 2012
  • Director's Citation, FDA, 2010
  • FACP, American College of Physicians, 1991
  • Alpha Omega Alpha (Junior Year), UC San Francisco, 1975
  • Phi Beta Kappa (Junior Year), UC Berkeley, 1971

Education & Training

Show all (5) Hide

  • BS Genetics UC Berkeley
  • Resident Internal Medicine UC San Francisco
  • Endocrinology Fellow Metabolic Research Unit UC San Francisco
  • MD School of Medicine UC San Francisco
  • Intern and Resident Internal Medicine UCLA Hospital

Interests

Show all (6) Hide

  • Bioengineering
  • Clinical pharmacology
  • Digital health
  • Diabetes
  • Diabetes technology
  • Cybersecurity

Websites

Show all (13) Hide

Publications (403)

Top publication keywords:
Insulin Infusion SystemsBlood Glucose Self-MonitoringHyperglycemiaDiabetes Mellitus, Type 1HypoglycemiaEquipment and SuppliesComputer SecurityDiabetes MellitusPancreas, ArtificialInsulinHypoglycemic AgentsDiabetes Mellitus, Type 2Injections, SubcutaneousBlood GlucoseMonitoring, Physiologic

Show all (398 more) Hide